# US 2019/0314320 A1 · Composition for treatment and/or prevention of peripheral nerve disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314320 A1
- Document ID: US20190314320A1
- Status: Published application
- Kind: A1
- Application number: 16/303,629
- Filed: 2017-05-22
- Published: 2019-10-17
- Earliest claimed: 2016-05-23
- Assignees: Osaka City University; Senju Pharmaceutical Co., Ltd.
- Applicants: Osaka City University; Senju Pharmaceutical Co., Ltd.
- Inventors: Shinji HIROTSUNE
- Web page: https://patentgrep.com/patent/US20190314320A1

## CPC

- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/351: not condensed with another ring
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/77: of oxiranes
- A61P 25/02: for peripheral neuropathies
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): R4O—R5m (IIa) wherein R4 is lower alkyl, R5 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

## Claims

### Claim 1

A method for treating and/or preventing peripheral nerve disorder, comprising administrating to a subject in need of treatment for peripheral nerve disorder a therapeutically effective amount of a compound represented by the general formula (I):
wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa):
R4O—R5m (IIa)
wherein R4 is lower alkyl, R is lower alkylene, and m is an integer of 1 to 6;
R2 is lower alkyl optionally substituted with phenyl; and
R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

### Claim 2 (depends on 1)

The method according to claim 1, wherein R1 is a group represented by the formula (IIa):
R4O—R5m (IIa)
wherein R4 is lower alkyl, R5 is lower alkylene, and m is an integer from 1 to 6.

### Claim 3 (depends on 1)

The method according to claim 1, wherein R1 is a group represented by the formula (IIb):
H3CO—CH2CH2n (IIb)
wherein n is an integer from 1 to 6.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the heterocyclic group that is a substituent for the lower alkyl represented by R1 is pyridyl optionally substituted with lower alkyl.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the heteroatom of the heterocyclic group represented by R1 is oxygen.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the lower alkyl represented by R3 is cyclopropyl.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is selected from:
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 2-methoxyethyl ester,
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester,
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 8-methoxy-3,6-dioxaoctyl ester,
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 1-methoxy-3,6,9-trioxaundecanyl ester, and
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 2-(pyridin-2-yl)ethyl ester.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the compound is administered by oral administration, injection, or intravenous drip.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is administered at a dose of from 0.1 to 2,000 mg per day.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the peripheral nerve disorder is at least one selected from the group consisting of mechanical or entrapment neuropathy, metabolic neuropathy, infectious neuropathy, and drug-induced peripheral nerve disorders.

### Claim 11

A method for treating and/or preventing peripheral nerve disorder, comprising administrating to a subject in need of treatment for peripheral nerve disorder a therapeutically effective amount of ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester.
